An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)
Status:
Completed
Trial end date:
2017-04-12
Target enrollment:
Participant gender:
Summary
This study consists of Part I and an optional Part II. The purpose of Part I is to compare
the plasma pharmacokinetics of verubecestat (MK-8931) following administration of a single
oral dose of 40 mg MK-8931 to participants with moderate hepatic insufficiency (HI) to that
of healthy matched controls. An interim safety and pharmacokinetic analysis on the basis of
Part I will be performed in order to support the decision to continue with the optional Part
II. If a decision to continue with Part II is made, participants with mild HI will be
enrolled to receive a single oral dose of 40mg MK-8931. If any healthy participants from Part
I do not meet the matching criteria for Part II additional healthy participants will be
enrolled.